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Abstract
Nocardiosis is an infrequent but potentially serious pulmonary infection that typically affects patients with immune suppres-
sion or structural lung disease. We report a case of a 70-year-old patient with chronic obstructive pulmonary disease (COPD)
treated with inhaled steroids, theophylline, short-acting beta-agonists and anticholinergics, and long-term oxygen therapy,
who presented with non-resolving pneumonia. Following a diagnosis of nocardiosis, made based on sputum culture, the
patient was treated with trimethoprim/sulphamethoxazole and then, due to treatment side effects, with minocycline. We
review the literature data on nocardiosis in COPD patients.
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Streszczenie
Nokardioza jest rzadkim, lecz potencjalnie ciężkim zakażeniem płuca, zwykle występującym u chorych z niedoborami odporności
lub z zaburzeniami struktury płuc. Przedstawiamy opis przypadku 70-letniej chorej z przewlekłą obturacyjną chorobą płuc (POChP)
leczoną przewlekle kortykosterydami wziewnymi, teofiliną, krótko działającymi beta-mimetykami i antycholinergikami oraz tlenote-
rapią domową, która zgłosiła się z powodu opornego na leczenie zapalenia płuc. Rozpoznanie nokardiozy postawiono na podstawie
posiewu plwociny, a następnie chorą leczono trimetoprimem/sulfametoksazolem i ze względu na pojawienie się działań niepożąda-
nych, minocykliną. Przedstawiamy dane literaturowe dotyczące występowania nokardiozy u chorych na POChP.
Słowa kluczowe: POChP, nokardioza, zapalenie płuc
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Introduction
Nocardiosis is an acute, subacute, or chronic
bacterial infection that is typically acquired thro-
ugh inhalation and usually presents with pulmo-
nary, central nervous system (CNS), and cutane-
ous manifestations [1, 2]. In the lung, Nocardia may
cause pulmonary nodules, infiltrates, cavitation, or
pleural effusion [2]. Nocardiosis is more likely to
affect people who are immunosuppressed or have
underlying lung disease. We report a case of no-
cardiosis in a patient with chronic obstructive
pulmonary disease (COPD), who presented with
a non-resolving pneumonia.
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ted with tachycardia to 123/min, and worsened hy-
poxemia requiring O2 supplementation at 50%.
Physical exam at that time showed bibasilar crac-
kles. Her WBC increased to 17 x 103/mm3 with neu-
trophilic predominance (82%) and arterial blood
gas showed a pH of 7.37, pO2 74 mm Hg, and pCO2
60 mm Hg. Chest X-ray showed progression of bi-
basilar infiltrates with possible pleural effusion.
Chest CT showed a dense right lower lobe conso-
lidation and  a less prominent left lower lobe infil-
trate  (Fig. 1). Sputum Gram stain and culture were
obtained, and vancomycin with piperacillin-tazo-
bactam were started for a suspected healthcare-as-
sociated pneumonia.
Sputum gram stain showed gram-positive
branching rods, suspicious for Nocardia species
(Fig. 2), which was later confirmed in culture as
N. asteroides. Antibiotics were switched to trime-
thoprim-sulphamethoxazole IV 5 mg/kg every
8 hours. The patient was discharged with a diagno-
sis of pulmonary nocardiosis and took trimetho-
prim/sulphamethoxazole 800/160 mg 2 tabs 3 ti-
mes a day with the plan to continue this therapy
for 3 months. The patient improved clinically, but
she developed urticaria on the chest, abdomen,
back, and extremities after about 1 month of the-
rapy. At this point, her therapy was switched to
minocycline 100 mg twice a day for an additional
two months. No follow-up CT chest was performed,
but a chest X-ray 4 months later showed resolu-
tion of right lower lobe pneumonia. She continu-
ed to use home oxygen therapy.
Case report
A 70-year-old female with severe COPD (sta-
ge IV according to GOLD based on the FEV1 of 39%
of predicted and chronic respiratory failure, on
long-term home oxygen therapy for three years)
and peripheral vascular disease, manifested by
intermittent claudication, presented to the hospi-
tal with shortness of breath and chest tightness.
The patient was discharged from the hospital ear-
lier in the day after being hospitalized for 4 days
for a COPD exacerbation. She had been treated
with supplemental oxygen, albuterol-ipratropium
nebulizers, methylprednisolone, and levofloxacin.
Her symptoms improved but recurred after she had
arrived home. On admission, she denied fever,
chills, sweating, palpitations, cough, and nausea;
other organ systems were reviewed and negative.
The patient had not had any other medical
problems or any prior surgeries. She was an ex-
smoker of 32 pack-years, quit smoking 25 years ago,
and denied alcohol and illicit drug use. She had
been retired for 20 years after working as a waitress
and a manager of an ice cream shop. Over the prior
6 months she had only had one admission for
COPD exacerbation. Environmental hazards inclu-
ded a recent month-long exposure to dust while
preparing for a garage sale. At the time of admis-
sion the patient was taking a prednisone taper (cur-
rent dose of 60 mg), levofloxacin 500 mg daily, flu-
ticasone inhaler 44 mcg 2 puffs twice a day, the-
ophylline 300 mg every eight hours, montelukast
10 mg every day, albuterol inhaler 2 puffs every
6 hours as needed, albuterol-ipratropium inhaler
2 puffs every 6 hours as needed, aspirin 81 mg eve-
ry day, and cilostazol 100 mg tab twice a day.
On physical examination she was tachycardic
and her other vital signs were normal, she was
normoxemic (92%) while receiving supplemental
O2 at 5 L/min, and had coarse breath sounds and
wheezing. Laboratory exams were normal with the
exception of elevated serum bicarbonate of 31 mM/L.
EKG showed sinus tachycardia, and the chest X-
ray demonstrated a right lower zone infiltrate.
For presumed COPD exacerbation, the patient
received supplemental oxygen and albuterol-ipra-
tropium nebulizer every 4 hours while awake.
Prednisone dose was maintained at 60 mg daily
and she continued to take levofloxacin (for a total
of 7 days), fluticasone, theophylline, and monte-
lukast. She was started on enoxaparin 40 mg sub-
cutaneously every day for prophylaxis for deep
vein thrombosis.
Five days after admission, the patient expe-
rienced a sudden onset of fever of 38.7oC, associa-
Figure 1. Computed tomography of the chest, showing a dense
right lower lobe infiltrate and a less prominent left lower lobe infil-
trate
Rycina 1. Tomografia komputerowa klatki piersiowej — zagęszcze-
nia miąższowe w płatach dolnych prawym i lewym
Michael Anderson, Tomasz J. Kuźniar, COPD and nocardiosis
567www.pneumonologia.viamedica.pl
Discussion
Nocardia spp. are ubiquitous bacteria that are
present in the soil, but also in long-standing dust,
sand, and stagnant water. Pulmonary nocardiosis
is rare; in the US, the estimated annual incidence
is 500 to 1000 cases [3]. It can take forms of acute,
subacute, or chronic infection that is acquired by
inhalation, and has a high likelihood for exacer-
bations and remissions [2]. Clinically, patients
present with cough (77%), fever (74%), sputum
(65%), dyspnoea (65%), chest pain (39%), and less
frequently with haemoptysis and abdominal pain
[2]. Radiographic findings are variable and non-
specific and have included a small nodule, bilate-
ral infiltrates, cavitation, upper lobe disease, pleu-
ral effusions, and bony erosions. There is a pro-
pensity to have neurological involvement as up to
25% of nocardiosis cases involve the CNS, mani-
festing as altered mental status, headache, and/or
neck stiffness.
Nocardia infections rarely affect an immuno-
competent host with no pulmonary pathology; they
are more likely to present in patients who are im-
munocompromised, have structural lung disease,
especially chronic obstructive pulmonary disease
(COPD), or have a history of surgery or trauma [4].
Other risk factors include corticosteroid use, un-
derlying malignancy, transplantation, autoimmu-
ne disease, acute immunodeficiency syndrome,
and intravenous drug abuse. In a large series of
cases, specific risk factors were present in 94% of
patients with nocardiosis, with the most common
being corticosteroid use and immunosuppressive
treatment [2]. Therefore, in any patient with pneu-
monia who is not improving on standard antibio-
tics, Nocardia should be considered, especially if
the above risk factors are present [5, 6].
In patients with COPD, bacterial colonization
of the lower airways alters ciliary motility and cau-
ses epithelial damage, which facilitates the presen-
ce of Nocardia; underlying structural lung disease
and long-term immunosuppressive effects of cor-
ticosteroids are additional risk factors in this pa-
tient population [4]. In our literature review, we
have identified 14 reports and 75 patients with a
dual diagnosis of COPD and nocardiosis (Tab. 1).
In the studies that reported corticosteroid therapy
(including our case report), 36 of 57 patients
(63.2%) were on steroid therapy for 21 days to 5
years prior to the diagnosis of nocardiosis. Most
cases reported predisposing factors in addition to
COPD and steroid therapy, which included bron-
chiectasis, pulmonary fibrosis, pneumoconiosis,
silicosis, aspergillosis, human immunodeficiency
virus (HIV) infection, and malignancy.
Diagnosis of nocardiosis is most frequently
based on sputum cultures. If the patient cannot
expectorate, then a bronchoscopy can be perfor-
med to collect a respiratory sample. Sputum cul-
tures are positive in approximately 90% of cases;
diagnostic yield can be as high as 100% for bron-
choalveolar lavage and/or transbronchial lung
biopsy [7]. In immunosuppressed patients, a posi-
tive sputum culture is more likely to indicate di-
sease rather than colonization, so these patients
must be treated [8]. Nocardia grows slowly (5–21
days) on a variety of aerobic media and is partial-
ly acid-fast.
Treatment usually involves a sulphonamide-
containing regimen such as trimethoprim-sulpha-
methoxazole (TMP-SMX); as sulpha allergies are
fairly common, effective alternatives include mi-
nocycline, amoxicillin-clavulanate, carbapenems,
amikacin, cefuroxime, and ceftriaxone. Inhaled
antibiotics (aminoglycosides) have proven to be
effective for pulmonary nocardiosis without the
risk of systemic toxicity [9]. In addition to sulpha
allergies, alternatives may be chosen due to incre-
asing resistance to TMP-SMX; testing for drug sen-
sitivities is therefore strongly recommended. Du-
ration of therapy may vary from 3 to 12 months
based on the patient’s clinical response.
Mortality of pulmonary nocardiosis has been
as high as 38.7% in one report, which has been
consistent with other studies [2]. This high morta-
lity likely reflects the frail condition of the patients
it affects, the difficulty in establishing the diagno-
sis, and incomplete response to treatment. In dis-
seminated disease, the mortality rate may reach
Figure 2. Gram stain of sputum, showing filamentous, Gram-positi-
ve branching rods, typical for Nocardia
Rycina 2. Barwienie plwociny metodą Grama — Gram-dodatnie
rozgałęzione strzępki, typowe dla Nocardia
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64%, with the rate in the presence of CNS invo-
lvement being 100% [2]. Therefore, patients who
develop pulmonary nocardiosis should be asses-
sed for disseminated nocardiosis with blood cul-
tures and brain imaging, either head CT or brain
MRI. Cerebro-spinal fluid analysis should be per-
formed if meningitis is suspected and there is no
mass effect seen with brain imaging. Other diagno-
stic methods that may be required are biopsy of
skin lesions and aspiration of abscesses.
Table 1. Literature review of reports of COPD and nocardiosis; FEV1 — forced exhaled volume in one second;
*NR — not reported, w/— with
Tabela 1. Przegląd literatury dotyczącej występowania nokardiozy u chorych na POChP; FEV1 — nasilona objętość
wydechowa 1-jednosekundowa; *NR — brak danych; w/— ze współistnieniem
Authors Number of Severity Oral steroid Duration of Inhaled Other Refe-
patients  of COPD dose (in mg of steroid therapy steroids predisposing rence
(FEV1 in L or prednisone) (yes/no) factors
 as % predicted)
Aide et al. (2008) 1 41.2% Only in acute exacerbation None Y (4 years) Bronchiectasis [3]
Hui et al. (2003) 10 NR 5 mg–50 mg range Months-years NR 2 w/Bronchopulmonary [10]
Aspergillosis
1 w/Bronchiectasis
1 w/Bronchiectasis
& Neutropenia
1 w/Pulmonary Fibrosis
1 w/Pulmonary
Fibrosis & Lung Cancer
1 w/metastatic colon cancer
1 w/Lymphoma
Lederman et al. (2004) 1 NR PO & IV for acute exacerbation NR NR Breast Cancer [4]
Mari et al. (2001) 6 0.56–1.12 L Average 13 mg/d w/range 2–5 yrs NR Pneumoconiosis [11]
7.5–25 mg in 4 patients in 1 patient
Maraki et al. (2009) 2 NR NR NR NR 1 pt w/renal transplant/ [12]
/immunosuppressant
1 pt on steroids for
rheumatoid arthritis
Martinez-Tomas et al. 7 NR 4 total on steroids Refer to Y 1 pt w/silicosis [2]
(2007) (1 on 30 mg daily for 21 days prev cell
& 2 on taper for 21 days
& 1 mo, respectively)
Menendez et al. (1997) 3 NR 1 pt on 30 mg 21 days NR 1 w/Bronchiectasis [7]
Minero et al. (2009) 8 NR 5 pts w/median Median of 2 months NR 1 w/Astrocytoma [13]
of 20 mg 1 w/Invasive Aspergillosis
1 w/Rheumatoid arthritis
1 w/Ankylosing Spondylitis
Munoz et al. (2007) 19 NR 9 pts on steroid therapy NR NR 1 w/lupus and  diabetes [14]
1 w/HIV
2 w/lymphoma
1 w/HIV & solid neoplasm
1 w/solid neoplasm
2 w/rheumatoid arthritis
Pelaez et al. (2009) 1 0.53 L 12.5 mg 20 months NR None [15]
Tuo et al. (2008) 9 NR NR NR NR 1 w/Pneumoconiosis [16]
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